Toripalimab Consolidation in Limited-Stage Small Cell Lung Cancer: GASTO-1052A Full Results Published in JITC
Start here
The full results of the GASTO-1052A study were published in the Journal for ImmunoTherapy of Cancer (JITC, IF=11.7). Toripalimab consolidation therapy significantly prolonged progression-free survival versus observation in limited-stage small cell lung cancer (LS-SCLC), with a PFS hazard ratio of 0.55.
Excerpted from WeChat
Coverage timeline
Follow the coverage to see the different angles.
- WeChatPickToripalimab Consolidation in Limited-Stage Small Cell Lung Cancer: GASTO-1052A Full Results Published in JITC
The full results of the GASTO-1052A study were published in the Journal for ImmunoTherapy of Cancer (JITC, IF=11.7). Toripalimab consolidation therapy significantly prolonged progression-free survival versus observation in limited-stage small cell lung cancer (LS-SCLC), with a PFS hazard ratio of 0.55.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 19 13:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.